Gilead Sciences GILD Royalty, contract and other revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's royalty, contract and other revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's royalty, contract and other revenues — total revenues?
- Gilead Sciences (GILD) reported royalty, contract and other revenues — total revenues of $14M in Q1 2026.
- How has Gilead Sciences's royalty, contract and other revenues — total revenues changed year-over-year?
- Gilead Sciences's royalty, contract and other revenues — total revenues decreased by 74.1% year-over-year, from $54M to $14M.
- What is the long-term trend for Gilead Sciences's royalty, contract and other revenues — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's royalty, contract and other revenues — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $297M to $527M.
- What does royalty, contract and other revenues — total revenues mean?
- Revenue earned from licensing intellectual property, royalties, and contractual service agreements rather than direct product sales.
- How do you interpret royalty, contract and other revenues — total revenues?
- An increase indicates successful monetization of intellectual property or expanded collaborative partnerships, while a decrease may suggest expiring patents or reduced reliance on third-party licensing models.
- How does royalty, contract and other revenues — total revenues compare across companies?
- Peers in the biopharmaceutical industry often report this as 'Other Revenue' or 'Licensing and Royalty Income,' which typically fluctuates based on the lifecycle of licensed drugs and the timing of milestone payments.